<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928365</url>
  </required_header>
  <id_info>
    <org_study_id>Cytokim-01</org_study_id>
    <nct_id>NCT04928365</nct_id>
  </id_info>
  <brief_title>Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy</brief_title>
  <official_title>Open Prospective Clinical Trial to Develop the Computer Software (Intelligent Prognostic System) for Predicting the Efficacy of Anti-PD-1 Immunotherapy of Melanoma Patients in Routine Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open prospective clinical trial to develop the computer software (Intelligent prognostic&#xD;
      system) for predicting the efficacy of anti-PD-1 immunotherapy of melanoma patients in&#xD;
      routine practice&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">March 25, 2023</completion_date>
  <primary_completion_date type="Actual">May 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokine profile</measure>
    <time_frame>up to 12 months</time_frame>
    <description>IL-2, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-22, (IFN)-α2, IFN-γ, NFβ/Lymphotoxin-α(LTA), MCP-1/CCL2,IP-10/CXCL10, MIG/CXCL9, GM-CSF, PDGF-AA, PDGF-AB/BB, VEGF-A</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Advanced melanoma patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage III and IV melanoma patients after radical surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-PD-1 monoclonal antibody</intervention_name>
    <description>Anti-PD-1 therapy</description>
    <arm_group_label>Advanced melanoma patients</arm_group_label>
    <arm_group_label>Stage III and IV melanoma patients after radical surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Morphological verification of cutaneous melanoma. Verification of metastases is not&#xD;
             necessary&#xD;
&#xD;
          2. ECOG 0-1&#xD;
&#xD;
          3. Age of patients - 18 years and older&#xD;
&#xD;
          4. No prior chemotherapy, immunotherapy, radiation or hormonal therapy&#xD;
&#xD;
          5. Adequate contraception for women of childbearing age&#xD;
&#xD;
          6. Written consent of the patient to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-compliance with the previously listed criteria&#xD;
&#xD;
          2. Pregnancy and breastfeeding&#xD;
&#xD;
          3. Therapy with systemic corticosteroids and/or other immunosuppressants within 4 weeks&#xD;
             before the screening or a high probability of the need for their use during the study&#xD;
             for the treatment of intercurrent pathology&#xD;
&#xD;
          4. History of another malignancy other than the study indication under this trial within&#xD;
             5 years of study enrollment. Does not apply to subjects who underwent successful&#xD;
             definitive resection of basal or squamous cell carcinoma of the skin, in situ cervical&#xD;
             cancer, in situ breast cancer, or other in situ cancers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irina N Mikhaylova, DSc</last_name>
    <phone>8 499 324 90 24</phone>
    <email>irmikhaylova@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Center, Kashirskoye shosse 23</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina N Mikhaylova, DSc</last_name>
      <phone>8 499 324 90 24</phone>
      <email>irmikhaylova@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 13, 2021</last_update_submitted>
  <last_update_submitted_qc>June 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Blokhin's Russian Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Irina Mikhaylova</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

